Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.25.1 (
proteasome
)
28,817
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Thyroid cancer patients with high miR-490-3p inhibit translation of
PCBP1
mRNA, whereas in patients with low miR-490-3p
PCBP1
mRNA expression is high; however, the resultant protein is targeted for degradation through the
proteasome
. The objective of the present study was to evaluate the molecular mechanism that regulates post-translation degradation of poly r(C) binding protein (PCBP) 1 expression in thyroid cancer cells. Mass spectrometric analysis of PCBP1 immunoprecipitates from MG-132 treated TPC1 cells revealed a list of ubiquitin ligases associated with PCBP1. RNAi-mediated silencing of the candidate ubiquitin ligases revealed that knockdown of the ubiquitin ligase
UBE4A
stabilized PCBP1 in TPC1 cells. Concurrent overexpression of the candidate ubiquitin ligases in the normal thyroid epithelial cell line Nthy-ori 3-1 confirmed that
ubiquitin conjugation factor E4 A
(
UBE4A
) is the ubiquitin ligase that is degrading PCBP1. Coimmunoprecipitation of HA-tagged PCBP1 in TPC1 cells cotransfected with FLAG-
UBE4A
revealed robust polyubiquitinated smear of PCBP1, thus confirming
UBE4A
as the ubiquitin ligase of PCBP1.
UBE4A
expression mimicked
PCBP1
mRNA expression in thyroid cancer patients and was inversely correlated to PCBP1 protein expression. Low
UBE4A
expression level was associated with a better prognosis in thyroid cancer patients. Our data reveal a post-translational regulatory mechanism of regulating PCBP1 expression in thyroid cancer cells.
...
PMID:Poly r(C) binding protein (PCBP) 1 expression is regulated by the E3 ligase UBE4A in thyroid carcinoma. 2896 76